Last update 01 Nov 2024
Shanghai Braegen Pharmaceuticals

Shanghai Braegen Pharmaceuticals

Private Company|
2015|
Guangdong Sheng, China
|
www.braegen.com.cn

Overview

Tags

Nervous System Diseases
Endocrinology and Metabolic Disease
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases4
Endocrinology and Metabolic Disease3
Top 5 Drug TypeCount
Small molecule drug5
Top 5 TargetCount
TrkB(Neurotrophic tyrosine kinase receptor type 2)2
LGMN(legumain)2
α-synuclein(Synuclein alpha)1

Related

5
Drugs associated with Shanghai Braegen Pharmaceuticals
BrAD-R13
Target
TrkB
Mechanism
TrkB stimulants
Active Org.
Braegen Pharmaceutical Co. [+1]
Originator Org.
Braegen Pharmaceutical Co.
Active Indication
Alzheimer Disease [+6]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Braegen-05
Target
α-synuclein
Mechanism
α-synuclein modulators
Active Org.
Shanghai Braegen PharmaceuticalsShanghai Braegen Pharmaceuticals
Originator Org.
Shanghai Braegen PharmaceuticalsShanghai Braegen Pharmaceuticals
Active Indication
Lewy Body Disease [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Braegen-04
Target
LGMN
Mechanism
LGMN inhibitors
Active Org.
Shanghai Braegen PharmaceuticalsShanghai Braegen Pharmaceuticals
Originator Org.
Shanghai Braegen PharmaceuticalsShanghai Braegen Pharmaceuticals
Active Indication-
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Shanghai Braegen Pharmaceuticals
CTR20233658 / Not yet recruitingPhase 1
评估在中国健康受试者进行的单中心、随机、双盲、单次、多次给药BrAD-R13的安全性、耐受性和药代动力学特征、食物影响和物质平衡研究。
[Translation] A single-center, randomized, double-blind, single- and multiple-dose study of BrAD-R13 was conducted in healthy Chinese subjects to evaluate its safety, tolerability, pharmacokinetic characteristics, food effects, and material balance.
100 Clinical Results associated with Shanghai Braegen Pharmaceuticals
Login to view more data
0 Patents (Medical) associated with Shanghai Braegen Pharmaceuticals
Login to view more data
100 Deals associated with Shanghai Braegen Pharmaceuticals
Login to view more data
100 Translational Medicine associated with Shanghai Braegen Pharmaceuticals
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
2
Phase 1 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Braegen-05
 ( α-synuclein )		Parkinson Disease
More
Phase 1
BrAD-R13
 ( TrkB )		Alzheimer Disease
More
Phase 1
Braegen-03
 ( LGMN )		Amyotrophic Lateral Sclerosis
More
Preclinical
Braegen-04
 ( LGMN )		-
Preclinical
CF3CN
 ( TrkB )		Alzheimer Disease
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free